AU7542301A - Encapsulation of plasmid DNA (lipogenes<sup>TM</sup>) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes - Google Patents

Encapsulation of plasmid DNA (lipogenes<sup>TM</sup>) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes

Info

Publication number
AU7542301A
AU7542301A AU7542301A AU7542301A AU7542301A AU 7542301 A AU7542301 A AU 7542301A AU 7542301 A AU7542301 A AU 7542301A AU 7542301 A AU7542301 A AU 7542301A AU 7542301 A AU7542301 A AU 7542301A
Authority
AU
Australia
Prior art keywords
sup
lipogenes
encapsulation
therapeutic agents
plasmid dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU7542301A
Inventor
Teni Boulikas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU7542301A publication Critical patent/AU7542301A/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
AU7542301A 2000-06-09 2001-06-08 Encapsulation of plasmid DNA (lipogenes<sup>TM</sup>) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes Pending AU7542301A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21092500P 2000-06-09 2000-06-09
PCT/US2001/018657 WO2001093836A2 (en) 2000-06-09 2001-06-08 Encapsulation of polynucleotides and drugs into targeted liposomes

Publications (1)

Publication Number Publication Date
AU7542301A true AU7542301A (en) 2001-12-17

Family

ID=22784880

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001275423A Ceased AU2001275423B2 (en) 2000-06-09 2001-06-08 Encapsulation of polynucleotides and drugs into targeted liposomes
AU7542301A Pending AU7542301A (en) 2000-06-09 2001-06-08 Encapsulation of plasmid DNA (lipogenes<sup>TM</sup>) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU2001275423A Ceased AU2001275423B2 (en) 2000-06-09 2001-06-08 Encapsulation of polynucleotides and drugs into targeted liposomes

Country Status (8)

Country Link
EP (1) EP1292284A2 (en)
JP (1) JP2003535832A (en)
CN (2) CN1981873A (en)
AU (2) AU2001275423B2 (en)
CA (1) CA2411542A1 (en)
MX (1) MXPA02012198A (en)
TW (1) TWI292324B (en)
WO (1) WO2001093836A2 (en)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7294401A (en) * 2000-06-16 2002-01-02 Zealand Pharmaceuticals As Peptide conjugates modified n- and/or c-terminally by short charged peptide chains
EP1328658A2 (en) * 2000-06-22 2003-07-23 San Diego State University Foundation Recombination modulators and methods for their production and use
GB0103110D0 (en) 2000-08-25 2001-03-28 Aventis Pharma Inc A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1
EP1360311B1 (en) * 2000-08-25 2008-04-09 Aventis Pharmaceuticals Inc. Membrane penetrating peptides and uses thereof
EP1358207A4 (en) * 2000-11-15 2004-07-21 Us Gov Health & Human Serv Sol-fusin: use of gp64-6his to catalyze membrane fusion
SE0101702D0 (en) 2001-05-15 2001-05-15 Ardenia Investments Ltd Novel potentiating compounds
AU2002362039B2 (en) 2001-12-03 2007-07-26 Soligenix, Inc Stabilized reverse micelle compositions and uses thereof
US20040052928A1 (en) 2002-09-06 2004-03-18 Ehud Gazit Peptides and methods using same for diagnosing and treating amyloid-associated diseases
US20070021345A1 (en) 2003-06-30 2007-01-25 Ehud Gazit Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
EP1587944A4 (en) 2002-03-01 2007-03-21 Dyax Corp Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
JP2003286198A (en) * 2002-03-29 2003-10-07 Japan Science & Technology Corp Therapeutic medicine using protein hollow nanoparticle expression growth factor, and the like
JP2003286199A (en) * 2002-03-29 2003-10-07 Japan Science & Technology Corp Therapeutic medicine for hepatic disease using protein hollow nanoparticle
EP3100719A3 (en) 2002-05-15 2017-02-22 California Pacific Medical Center Delivery of nucleic acid-like compounds
EP2108362B1 (en) 2002-06-26 2013-05-29 MediGene AG A cationic liposomal preparation comprising a taxane
DK1519714T3 (en) 2002-06-28 2011-01-31 Protiva Biotherapeutics Inc Method and apparatus for preparing liposomes
CA2495913A1 (en) * 2002-08-23 2004-03-04 Medigene Oncology Gmbh Non-vesicular cationic lipid formulations
US7491699B2 (en) 2002-12-09 2009-02-17 Ramot At Tel Aviv University Ltd. Peptide nanostructures and methods of generating and using the same
EP2058275A1 (en) 2003-01-07 2009-05-13 Ramot at Tel-Aviv University Ltd. Peptide nanostructures encapsulating a foreign material and method of manufacturing same
EP1603535A4 (en) * 2003-03-18 2008-10-15 Ethicon Inc Aromatase inhibitor diagnosis and therapy
EP1793816B1 (en) 2004-08-19 2012-01-04 Tel Aviv University Future Technology Development L.P. Compositions for treating amyloid associated diseases
JP4810825B2 (en) * 2004-12-27 2011-11-09 東洋紡績株式会社 Lipase activity measuring method and measuring reagent
WO2006086330A2 (en) * 2005-02-08 2006-08-17 Id Biomedical Corporation Of Quebec C.O.B. As Glaxosmithkline Biologicals North America Pharmaceutical compositions
JP5067733B2 (en) * 2005-03-09 2012-11-07 国立大学法人北海道大学 Lipid membrane structure capable of delivering target substance into mitochondria
WO2006101201A1 (en) * 2005-03-24 2006-09-28 National University Corporation Hokkaido University Liposome capable of effective delivery of given substance into nucleus
US10004828B2 (en) 2005-10-11 2018-06-26 Romat at Tel-Aviv University Ltd. Self-assembled Fmoc-ff hydrogels
CN100376680C (en) * 2005-11-01 2008-03-26 暨南大学 Dual target effected chimera recombinant, its construction method and application
EP1790657A1 (en) * 2005-11-24 2007-05-30 Technische Universität München pH-switchable transmembrane peptides as stimulators of membrane fusion
GR20060100144A (en) * 2006-03-03 2007-10-17 Cancer treatment using oxaliplatin encapsulated into liposomes and co-encapsulation into the liposome particle of more than one pharmaceutical preparations, or genes
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
KR101129509B1 (en) 2006-10-03 2012-04-13 알닐람 파마슈티칼스 인코포레이티드 Lipid containing formulations
AU2007316416A1 (en) * 2006-11-07 2008-05-15 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Self-assembling nanoparticles composed of transmembrane peptides and their application for specific intra-tumor delivery of anti-cancer drugs
CA2684321A1 (en) * 2007-03-21 2008-09-25 Effat Emamian Compositions comprising pkac fragments and uses thereof for inhibiting akt1, p70s6k or abl activity
CN101801340A (en) * 2007-06-28 2010-08-11 新加坡科技研究局 Cationic peptide for delivering an agent into a cell
JP2009203174A (en) * 2008-02-26 2009-09-10 Hokkaido Univ Iontophoresis composition comprising protein-liposome complex
HUE034483T2 (en) 2008-04-15 2018-02-28 Protiva Biotherapeutics Inc Novel lipid formulations for nucleic acid delivery
WO2010149785A1 (en) * 2009-06-26 2010-12-29 Universiteit Gent Cationic liposomes for the delivery of high molecular weight compounds
WO2011000107A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Novel lipid formulations for delivery of therapeutic agents to solid tumors
CN102038640B (en) * 2009-10-26 2013-11-13 石药集团中奇制药技术（石家庄）有限公司 Liposome medicament containing cholesterol PEG modifier and preparation method thereof
WO2012000104A1 (en) 2010-06-30 2012-01-05 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
DK2591114T3 (en) 2010-07-06 2016-08-29 Glaxosmithkline Biologicals Sa Immunization of large mammals with low doses of RNA
WO2012006378A1 (en) 2010-07-06 2012-01-12 Novartis Ag Liposomes with lipids having an advantageous pka- value for rna delivery
LT3243526T (en) 2010-07-06 2020-02-10 Glaxosmithkline Biologicals S.A. Delivery of rna to trigger multiple immune pathways
DK2611461T3 (en) * 2010-08-31 2022-05-16 Glaxosmithkline Biologicals Sa Pegylated liposomes to release RNA encoding immunogen
WO2012051211A2 (en) 2010-10-11 2012-04-19 Novartis Ag Antigen delivery platforms
EP2640737B1 (en) 2010-11-15 2018-08-29 Ramot at Tel-Aviv University Ltd. Dipeptide analogs for treating conditions associated with amyloid fibril formation
US9018169B2 (en) * 2011-03-18 2015-04-28 Duke University Peptides for suppressing inflammation
US9303063B2 (en) 2011-03-18 2016-04-05 Duke University Peptide compounds for suppressing inflammation
ES2656050T3 (en) 2011-07-06 2018-02-22 Glaxosmithkline Biologicals Sa Immunogenic combination compositions and uses thereof
SI2750707T1 (en) 2011-08-31 2019-02-28 Glaxosmithkline Biologicals Sa Pegylated liposomes for delivery of immunogen-encoding rna
WO2013110120A1 (en) * 2012-01-24 2013-08-01 Inter-K Pty Limited Peptide agents for cancer therapy
CN105101951B (en) * 2012-10-29 2021-08-03 新加坡科技研究局 Novel reagent for gene-drug therapy
CN103211762B (en) * 2013-04-11 2015-01-14 同济大学 Novel diagnosis and treatment integrated hybridization micelle and preparation method thereof
SG10201912038TA (en) 2014-04-23 2020-02-27 Modernatx Inc Nucleic acid vaccines
WO2016044902A1 (en) * 2014-09-26 2016-03-31 Sociedade Regional De Ensino E Saúde Ss Ltda Pharmaceutical composition of 15-deoxy-delta-12,14-prostaglandin j2 in a poloxamer-based micellar system and its use for treatment of inflammatory conditions
EP3307890A1 (en) 2015-06-10 2018-04-18 Board of Regents, The University of Texas System Use of exosomes for the treatment of disease
BR112018008090A2 (en) * 2015-10-22 2018-11-13 Modernatx Inc herpes simplex virus vaccine.
CA3024129A1 (en) * 2016-05-16 2017-11-23 The Board Of Regents Of The University Of Texas System Cationic sulfonamide amino lipids and amphiphilic zwitterionic amino lipids
CA3031705A1 (en) 2016-07-29 2018-02-01 Janssen Pharmaceutica Nv Treatment of prostate cancer with niraparib
AU2017345766A1 (en) 2016-10-21 2019-05-16 Modernatx, Inc. Human cytomegalovirus vaccine
US11752206B2 (en) 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
CN111212632B (en) 2017-08-25 2024-04-16 隆萨销售股份公司 Preparation of therapeutic exosomes using membrane proteins
US10723782B2 (en) 2017-12-28 2020-07-28 Codiak Biosciences, Inc. Exosomes for immuno-oncology and anti-inflammatory therapy
US11633482B2 (en) * 2017-12-29 2023-04-25 Suzhou Ribo Life Science Co., Ltd. Conjugates and preparation and use thereof
EP3938379A4 (en) 2019-03-15 2023-02-22 ModernaTX, Inc. Hiv rna vaccines
KR102101179B1 (en) * 2019-09-20 2020-05-15 건양대학교 산학협력단 Manufacturing Method of Nanocomplex for targeted theraphy in breast cancer stem cell(BCSC)
KR102164218B1 (en) * 2019-09-24 2020-10-12 코스맥스 주식회사 Multilayer cationic liposome for enhancing the skin penetration and preparation method thereof
WO2022045009A1 (en) * 2020-08-24 2022-03-03 国立大学法人山口大学 Composition for fluid tracing and fluid tracing method
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
EP4251170A1 (en) 2020-11-25 2023-10-04 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids, and related methods of use
CN114762679B (en) * 2021-01-13 2023-04-07 上海交通大学医学院 Nano composite and preparation method and application thereof
CN113406957B (en) * 2021-05-19 2022-07-08 成都理工大学 Mobile robot autonomous navigation method based on immune deep reinforcement learning
CN113546180A (en) * 2021-05-25 2021-10-26 重庆医科大学 Gene delivery vector with myocardial targeting and preparation method thereof
WO2023001156A1 (en) * 2021-07-19 2023-01-26 Wuhan University Compositions and methods for effective delivery of polynucleotides to cells
EP4230638A1 (en) * 2022-02-16 2023-08-23 Lipotrue, S.L. Peptides and compositions for use in cosmetics
CN114632062A (en) * 2022-03-21 2022-06-17 南京大学 Neutral liposome for delivering nucleic acid medicament and preparation method and application thereof
WO2023230587A2 (en) 2022-05-25 2023-11-30 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635487A (en) * 1994-12-29 1997-06-03 Wolff; Jon A. Amphipathic, micellar delivery systems for biologically active polyions
US6120794A (en) * 1995-09-26 2000-09-19 University Of Pittsburgh Emulsion and micellar formulations for the delivery of biologically active substances to cells
FR2754272B1 (en) * 1996-10-08 1998-11-13 Rhone Poulenc Rorer Sa PROCESS FOR THE PREPARATION OF COMPOSITIONS FOR TRANSFERRING NUCLEIC ACIDS
US6210717B1 (en) * 1997-12-12 2001-04-03 Samyang Corporation Biodegradable mixed polymeric micelles for gene delivery

Also Published As

Publication number Publication date
CN1444472A (en) 2003-09-24
TWI292324B (en) 2008-01-11
CA2411542A1 (en) 2001-12-13
CN1254234C (en) 2006-05-03
WO2001093836A3 (en) 2002-10-03
AU2001275423B2 (en) 2007-01-11
WO2001093836A2 (en) 2001-12-13
MXPA02012198A (en) 2004-08-19
EP1292284A2 (en) 2003-03-19
JP2003535832A (en) 2003-12-02
CN1981873A (en) 2007-06-20

Similar Documents

Publication Publication Date Title
AU7542301A (en) Encapsulation of plasmid DNA (lipogenes&lt;sup&gt;TM&lt;/sup&gt;) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes
HUP0105043A2 (en) Medicinal formulations containing an opioid and an alpha-antagonist
PL358335A1 (en) Polyglutamic acid-camptothecin conjugates and methods of preparation
AU2001237827A1 (en) Radioactive therapeutic liposomes
EP1073490A4 (en) Improved drug delivery device and methods therefor
AU2001266264A1 (en) System and methods for optimized drug delivery and progression of diseased and normal cells
EP1165048A4 (en) Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
AU2905199A (en) Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
EP1087753A4 (en) Targeted liposomal drug delivery system
HK1045462A1 (en) Combined preparations comprising morpholine anthracyclines and anticancer agent
IL146842A0 (en) Polymer conjugates of hedgehog proteins and uses
IL153853A0 (en) Bifunctional molecules and vectors complexed therewith for targeted gene delivery
AU7122801A (en) New aporphine esters and their use in therapy
FR2796397B1 (en) FELIN CALICIVIRUS GENES AND VACCINES, INCLUDING RECOMBINANT VACCINES
BR0016864A (en) Iron chelator supply system, and methods of preparing an iron chelator supply system and treatment of iron overload in a mammal in need of treatment
EP1185545A4 (en) Cd4-independent hiv envelope proteins as vaccines and therapeutics
HUP0300334A3 (en) Pharmaceutical preparations and their manufacture
IL149209A0 (en) N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them
AU1490801A (en) Targeted delivery of therapeutic and diagnostic moieties
EP1316560A4 (en) Novel human cancer/testis antigen and gene thereof
AU2001290147A1 (en) Transfection using plasmid preparations
EP1064026A4 (en) Enhancement of intracellular delivery and tissue targeting of drugs and genes
IL131719A0 (en) Iren protein its preparation and use
AU2001264824A1 (en) Vaccine and gene therapy vector and methods of use thereof
IL132531A0 (en) Detection and therapy of tumors